LLY

885.61

-0.67%↓

NVO

141.01

+0.18%↑

UNH

484.21

+0.76%↑

JNJ

147.77

+1.43%↑

MRK

129.72

+1.41%↑

LLY

885.61

-0.67%↓

NVO

141.01

+0.18%↑

UNH

484.21

+0.76%↑

JNJ

147.77

+1.43%↑

MRK

129.72

+1.41%↑

LLY

885.61

-0.67%↓

NVO

141.01

+0.18%↑

UNH

484.21

+0.76%↑

JNJ

147.77

+1.43%↑

MRK

129.72

+1.41%↑

LLY

885.61

-0.67%↓

NVO

141.01

+0.18%↑

UNH

484.21

+0.76%↑

JNJ

147.77

+1.43%↑

MRK

129.72

+1.41%↑

LLY

885.61

-0.67%↓

NVO

141.01

+0.18%↑

UNH

484.21

+0.76%↑

JNJ

147.77

+1.43%↑

MRK

129.72

+1.41%↑

Search

Amgen Inc

Closed

Sector Healthcare

309.8 1.23

Overview

Share price change

24h

Current

Min

303.1

Max

310.26

Key metrics

By Trading Economics

Income

-880M

-113M

Sales

-746M

7.5B

P/E

Sector Avg

20.474

23.904

EPS

3.96

Dividend yield

3.838

Profit margin

-1.517

Employees

26,700

EBITDA

-1.5B

2.2B

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+4.93 upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

3.84%

7.76%

Next Earnings

1 sie 2024

Next Dividend date

6 wrz 2024

Next Ex Dividend date

15 sie 2024

Market Stats

By TradingEconomics

Market Cap

-6.2B

159B

Previous open

308.57

Previous close

309.8

News Sentiment

By Acuity

12%

88%

8 / 369 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

Amgen Inc Chart

Related News

2 maj 2024, 20:42 UTC

Earnings

Amgen Posts Higher 1Q Revenue, Swings to Loss

6 lut 2024, 21:48 UTC

Earnings

Amgen 4Q Revenue Surges as Acquisition Boosts Results

19 cze 2024, 05:30 UTC

Top News
Acquisitions, Mergers, Takeovers

M&A Is Back. 4 Stocks That Could Be Targets. -- Barrons.com

3 maj 2024, 14:43 UTC

Hot Stocks

Stocks to Watch Friday: Apple, Amgen, Exxon, Coinbase -- WSJ

3 maj 2024, 11:43 UTC

Market Talk
Earnings

Amgen's Weight-Loss Drug Prospects Win New Bull -- Market Talk

3 maj 2024, 08:45 UTC

Earnings
Hot Stocks

Stocks to Watch Friday: Apple, Amgen, Block -- WSJ

3 maj 2024, 08:28 UTC

Earnings

These Stocks Are Moving the Most Today: Apple, Amgen, Expedia, Block, Coinbase, Cloudflare, Fortinet, and More -- Barrons.com

2 maj 2024, 20:04 UTC

Earnings

Amgen: FY Share Repurchases Not to Exceed $500 M >AMGN

2 maj 2024, 20:04 UTC

Earnings

Amgen Sees FY Capital Expenditure About $1.1B >AMGN

2 maj 2024, 20:03 UTC

Earnings

Amgen 1Q Adj EPS $3.96 >AMGN

2 maj 2024, 20:01 UTC

Earnings

Amgen 1Q Worldwide Enbrel Sales $567M >AMGN

2 maj 2024, 20:01 UTC

Earnings

Amgen 1Q Worldwide Prolia Sales $999M >AMGN

2 maj 2024, 20:01 UTC

Earnings

Amgen 1Q Worldwide XGEVA Sales $561M >AMGN

2 maj 2024, 20:01 UTC

Earnings

Amgen 1Q Rev $7.45B >AMGN

2 maj 2024, 20:01 UTC

Earnings

Amgen 1Q Worldwide Neulasta Sales $118M >AMGN

2 maj 2024, 20:01 UTC

Earnings

Amgen Sees FY EPS $7.15-EPS $8.40 >AMGN

2 maj 2024, 20:01 UTC

Earnings

Amgen Sees FY Adj EPS $19.00-Adj EPS $20.20 >AMGN

2 maj 2024, 20:01 UTC

Earnings

Amgen 1Q Loss/Shr 21c >AMGN

2 maj 2024, 20:01 UTC

Earnings

Amgen 1Q Loss $113M >AMGN

2 maj 2024, 20:01 UTC

Earnings

Amgen Sees FY Rev $32.5B-$33.8B >AMGN

11 kwi 2024, 14:46 UTC

Acquisitions, Mergers, Takeovers

Vertex Pharmaceuticals Seeks a Second Act With $4.9B Deal to Buy Alpine Immune -- Barrons.com

6 lut 2024, 21:44 UTC

Earnings

Amgen Rides Nine Record-Making Products To A Fourth-Quarter Sales Beat -- IBD

6 lut 2024, 21:01 UTC

Earnings

Amgen Sees FY Rev $32.4B-$33.8B >AMGN

6 lut 2024, 21:01 UTC

Earnings

Amgen 4Q EPS $1.42 >AMGN

6 lut 2024, 21:01 UTC

Earnings

Amgen 4Q Worldwide Enbrel Sales $1.01B >AMGN

6 lut 2024, 21:01 UTC

Earnings

Amgen 4Q Net $767M >AMGN

6 lut 2024, 21:01 UTC

Earnings

Amgen 4Q Worldwide Prolia Sales $1.11B >AMGN

6 lut 2024, 21:01 UTC

Earnings

Amgen 4Q Worldwide Neulasta Sales $239M >AMGN

6 lut 2024, 21:01 UTC

Earnings

Amgen 4Q Worldwide XGEVA Sales $527M >AMGN

6 lut 2024, 21:01 UTC

Earnings

Amgen 4Q Rev $8.2B >AMGN

Peer Comparison

Price change

Amgen Inc Forecast

Price Target

By TipRanks

4.93% upside

12 Months Forecast

Average 321.07 USD  4.93%

High 380 USD

Low 215 USD

Based on 20 Wall Street analysts offering 12 month price targets forAmgen Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

20 ratings

11

Buy

8

Hold

1

Sell

Technical Score

By Trading Central

304.31 / 306.4Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Bullish Evidence

Long Term

Bullish Evidence

Sentiment

By Acuity

8 / 369 Ranking in Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Amgen Inc

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq). It focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.